Impact of therapy with tumor necrosis factor-α inhibitors on the working ability of patients with ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic progressive disease resulting in disability. Affecting mainly young and able-bodied people, AS considerably reduces the manpower of society. To date, it may be stated on the basis of the available data, that long-term therapy with tumor necrosis factor-α inhi...
Main Authors: | Sh. F. Erdes, M. V. Podryadnova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2016-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/674 |
Similar Items
-
Use of inhibitors of tumor necrosis factor α in women with ankylosing spondylitis
by: O. A. Krichevskaya, et al.
Published: (2021-10-01) -
The abilities of golimumab in the therapy of ankylosing spondylitis
by: Sh. F. Erdes
Published: (2014-09-01) -
Efficacy of golimumab in treating uveitis in patients with ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2016-09-01) -
The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01) -
The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)